2018
DOI: 10.1007/s10637-018-0617-6
|View full text |Cite
|
Sign up to set email alerts
|

Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial

Abstract: Background A global multicenter study demonstrated superiority of carboplatin + nab-paclitaxel (PTX) therapy compared to carboplatin + PTX in terms of response rate (RR) and non-inferiority in terms of progression free survival (PFS) and overall survival (OS) in untreated patients with stage IIIB/IV non-small cell lung cancer; no clinical findings have so far been reported on maintenance therapies with nab-PTX. The aim of this study was to determine the efficacy and safety of maintenance therapy with nab-PTX f… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

3
3
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(6 citation statements)
references
References 18 publications
3
3
0
Order By: Relevance
“…Grade 3 and 4 adverse events included neutropenia (6 patients [16.7%]), increased ALT (1 [2.8%]), and increased bilirubin (1 (2.8%]). The toxicity profile was similar to that reported in previous studies [ 37 42 ].…”
Section: Resultssupporting
confidence: 88%
See 1 more Smart Citation
“…Grade 3 and 4 adverse events included neutropenia (6 patients [16.7%]), increased ALT (1 [2.8%]), and increased bilirubin (1 (2.8%]). The toxicity profile was similar to that reported in previous studies [ 37 42 ].…”
Section: Resultssupporting
confidence: 88%
“…In the present study, grade 3 or 4 adverse events were neutropenia in 16.7% of patients, increased ALT in 2.8%, and increased bilirubin in 2.8%. Such a favorable profile was similar to that observed for nab-paclitaxel combined with platinum in patients with advanced NSCLC [ 37 42 ].…”
Section: Discussionsupporting
confidence: 76%
“…Recently, it has been reported that nab -paclitaxel combined with carboplatin showed higher efficacy and less toxicity such as neuropathy, neutropenia, myalgia, and arthralgia in the treatment of NSCLC compared to carboplatin plus solvent-based paclitaxel [9]. In addition, maintenance monotherapy with nab -paclitaxel following combination chemotherapy with carboplatin plus nab -paclitaxel is reported to be a useful treatment option for patients with advanced NSCLC [14]. Based on these findings, our patients received the same regimen.…”
Section: Discussionmentioning
confidence: 99%
“…In phase II and III trials, nab‐PTX and carboplatin significantly increased the objective response rate (ORR) in comparison with conventional PTX in patients with untreated advanced NSCLC. 11 , 12 , 13 , 14 , 15 Moreover, nab‐PTX monotherapy showed antitumor activity against untreated advanced NSCLC in a phase I/II study. 16 However, its role as third‐line or later‐line chemotherapy for previously treated NSCLC has not been clarified.…”
Section: Introductionmentioning
confidence: 99%
“…Nab‐PTX reduces the risk of anaphylaxes triggered by Cremophor EL compared with conventional PTX. In phase II and III trials, nab‐PTX and carboplatin significantly increased the objective response rate (ORR) in comparison with conventional PTX in patients with untreated advanced NSCLC 11–15 . Moreover, nab‐PTX monotherapy showed antitumor activity against untreated advanced NSCLC in a phase I/II study 16 .…”
Section: Introductionmentioning
confidence: 99%